Arbutus Biopharma Corp. Hits New 52-Week High at $5.44

Arbutus Biopharma Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 5.44 on August 21, 2026. This achievement underscores the company's robust performance, as it has recorded a remarkable 65.92% increase over the past year, significantly outperforming the S&P 500, which saw a gain of 20.47% during the same period. The company has demonstrated impressive growth metrics, including a staggering 16,943.39% increase in net sales, with reported figures of USD 180.18 million for the half-year. Additionally, Arbutus Biopharma has shown consistent positive results over the last four consecutive quarters, highlighting its operational strength. Despite a negative return on equity of -29.24%, the stock's price-to-book ratio stands at 10.95, indicating an attractive valuation. Institutional holdings are notably high at 81.65%, reflecting confidence from larger investors. With a market capitalization of USD 839 million, Arbutus Biopharma continues to position itself as a noteworthy entity in the biotechnology landscape.